Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ephedrine Alkaloid AERs Release Without FDA Analysis Urged By SBA

This article was originally published in The Tan Sheet

Executive Summary

Release of a negative FDA analysis with recent adverse event reports on ephedrine alkaloid-containing dietary supplements "could eliminate the market for these products without FDA ever needing to continue its rulemaking," the Small Business Administration says in a March 17 letter to the agency.
Advertisement

Related Content

Ephedrine Alkaloid Weight-Loss Claims Proposed Ban Lifted By FDA
Ephedrine Alkaloid Weight-Loss Claims Proposed Ban Lifted By FDA
Ephedrine Alkaloid Weight-Loss Claims Proposed Ban Lifted By FDA
Ephedrine alkaloids
Ephedrine alkaloids

Topics

Advertisement
UsernamePublicRestriction

Register

PS091011

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel